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Pulmonary fibrosis is the most frequent form of interstitial lung disease. Effective therapies 
are not yet available; novel therapeutic approaches are needed for counteracting fibrosis. 
Poly(ADP-ribose) polymerases are enzymes, involved in DNA repair and cell apoptosis. 
PARP-1 deficient mice exhibited reduced lung fibrosis in response to bleomycin treatment 
compared to wild-type controls. Histamine H4 receptors (H4Rs) have been recognized as 
a new target for inflammatory and immune diseases, and H4R ligands reduced inflammation 
and oxidative stress in lung tissue. The aim of the study was to evaluate the cross-talk 
between PARP-1 and H4R in a model of bleomycin-induced lung fibrosis in PARP-1−/− and 
WT mice. Animals were treated with bleomycin or saline by intra-tracheal injection. 
JNJ7777120, an H4R antagonist, or VUF8430, an H4R agonist, were administered i.p for 
21 days. Airway resistance to inflation was evaluated, and lung tissues were processed 
for PARylated protein content, oxidative stress evaluation, and histology of small bronchi. 
The levels of pro-inflammatory (IL-1β and TNF-α), regulatory (IL-10), and pro-fibrotic (TGF-β) 
cytokines were evaluated. The deposition of αSMA was determined by immunofluorescence 
analysis. The results indicate that JNJ7777120 reduces PARylated protein production, 
decreases oxidative stress damage, and MPO, a marker for leukocyte tissue infiltration, 
in PARP-1−/− mice. A significant decrease in the production of both IL-1β and TNF-α and 
a significant increase in IL-10 levels are observed in mice treated with H4R antagonist, 
suggesting a crucial anti-inflammatory activity of JNJ7777120. The smooth muscle layer 
thickness, the goblet cell relative number, and collagen deposition decreased following 
JNJ7777120 administration. The H4R antagonist treatment also reduces TGF-β production 
and αSMA deposition, suggesting an important role of JNJ7777120 in airway remodeling. 
Our results show that PARylation is essential for the pathogenesis of pulmonary fibrosis 
and propose that PARP-1 and H4Rs are both involved in inflammatory and fibrotic 
responses. JNJ7777120 treatment, in a condition of PARP-1 inhibition, exerts anti-
inflammatory and anti-fibrotic effects, reducing airway remodeling and bronchoconstriction. 
Therefore, selective inhibition of H4Rs together with non-toxic doses of selective PARP-1 
inhibitors could have clinical relevance for the treatment of idiopathic pulmonary fibrosis.
Keywords: histamine H4 receptors, poly(ADP-ribose) polymerase 1, pulmonary fibrosis, inflammation, 
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a severe and progressive 
lung disease with approximately 3  years of median survival 
from the time of diagnosis and great associated morbidity, 
with wide-ranging negative effects on quality of life (Swigris 
et  al., 2005). Despite recent advances in understanding the 
disease pathobiology, IPF remains a disease with a poor 
prognosis and an incompletely understood pathogenesis. In 
the last few years, the European Medicines Agency and the 
Food and Drug Administration (FDA) approved the use of 
nintedanib and pirfenidone as new safe drugs for IPF 
treatment. However, effective treatments are not available, 
and new therapeutic strategies are needed as alternative 
options when the standards of care are not sufficient or 
effective (Wynn, 2007; Paz and Shoenfeld, 2010).
Despite an unknown etiology, many studies identified a 
significant genetic risk associated with the development of IPF, 
such as SFTPC, MUC5B, and telomerase mutations; however, 
mechanisms by which genetic risk factors promoting IPF remain 
unclear (Allen et al., 2017). It has been proposed that pulmonary 
fibrosis is due to an augmented proliferation of fibroblasts with 
massive formation and accumulation of extracellular matrix 
(ECM) proteins (e.g., vimentin, collagen, and fibronectin) that 
eventually damage lung function (Wilson and Wynn, 2009). 
Deposition of “scar” tissue in the interstitium of the lung causes 
an alteration in the homeostatic cross-talk between epithelial 
and mesenchymal cells. Epithelial cells secrete anti-fibrotic 
mediators like prostaglandin E2 (PGE2) (Lama et al., 2002); thus, 
the loss of epithelial cells results in lower levels of PGE2, which 
in turn, can allow resident fibroblasts to proliferate and differentiate 
into alpha-smooth muscle actin (αSMA) positive myofibroblasts 
(Kolodsick et al., 2003). Additionally, the release of the transforming 
growth factor-β (TGF-β), the most potent pro-fibrotic growth 
factor, promotes apoptosis of epithelial cells while simultaneously 
prevents apoptosis in lung fibroblasts (Thannickal and Horowitz, 
2006). The apoptosis paradox allows resident fibroblasts to 
accumulate and become myofibroblasts. Myofibroblasts, organized 
into agglomerations of cells known as fibroblastic foci, are highly 
secretory cells producing an excessive tissue matrix, especially 
collagen, and highly contractile cells causing distortion of the 
alveolar architecture. When the synthesis of new collagen by 
myofibroblasts overcomes its degradation rate, pulmonary fibrosis 
occurs leading to the accumulation of collagen (Wynn, 2008), 
the common pathological hallmark of fibrotic disorders. This 
process results in multiple alterations in the lung structure, with 
progressive thickening of the air-blood membrane and airway 
stiffening; these lesions impair both gas diffusion and ventilation/
perfusion relationship, with reduction or loss of gas exchange 
capacity (Plantier et  al., 2018).
Poly(ADP-ribose) polymerases (PARPs) are enzymes, involved 
in DNA repair and apoptosis. PARP-1 is the most abundant 
member of the PARP family and the most widely studied 
enzyme of this class. PARP-1 is activated upon binding to 
single- and double-strand DNA breaks via its N-terminal zinc 
finger domains (Ali et  al., 2012; Langelier et  al., 2012). Once 
activated by DNA damage, PARP-1 widely poly(ADP-ribosyl)
ates itself and promotes the enrollment of DNA repair proteins 
that are required for lesion processing and repair. However, 
when DNA damage is severe, PARP-1 becomes over-activated 
leading to excessive consumption of NAD+ and consequently 
to depletion of ATP that results in cellular dysfunction and 
necrotic cell death.
It has been reported that PARP activation characterizes a 
key pathway in many pathophysiological conditions associated 
with inflammation and oxidative stress. Interestingly, genes 
targeting approaches and the use of non-selective inhibitors 
have shown that PARP-1 is involved in a number of fibrotic 
diseases affecting the heart (Pacher et  al., 2002), liver 
(Mukhopadhyay et  al., 2014), vessels (Abdallah et  al., 2007), 
and lungs (Genovese et  al., 2005). Moreover, recent studies 
demonstrated that genetic depletion and pharmacological 
inhibition of PARP-1 reduced pulmonary fibrosis in an animal 
model of bleomycin-induced lung injury (Hu et  al., 2013; 
Lucarini et  al., 2017), suggesting that PARylation is important 
for myofibroblast differentiation and for the pathogenesis of 
the disease.
Histamine H4 receptor (H4R) has been identified as a novel 
target for inflammatory and immune disorders (Gschwandtner 
et al., 2013). Recent studies demonstrated that H4Rs are involved 
in the prevention of fibronectin-induced lung fibroblast 
migration, suggesting these receptors as new targets for the 
treatment of lung fibrosis (Kohyama et  al., 2010). Moreover, 
H4R antagonists significantly reduce goblet cell hyperplasia 
and collagen deposition in a model of allergic asthma (Masini 
et  al., 2013) and decrease inflammation and oxidative stress 
in a bleomycin-induced lung injury model (Rosa et  al., 2014; 
Lucarini et  al., 2017).
However, the cellular mechanism underlying the beneficial 
effects of H4R antagonists in lung diseases are not completely 
understood, and this topic needs to be  investigated in details.
The aim of the present study is to evaluate a possible 
involvement of PARP-1 in the H4R antagonists’ beneficial effects 
in reducing airway inflammation and remodeling. For this 
purpose, we evaluated the effects of the H4R-selective antagonist, 
JNJ7777120, and of the H4R agonist, VUF8430, in an in vivo 
model of bleomycin-induced lung fibrosis, in PARP-1 knock-out 
and in wild-type mice.
MATERIALS AND METHODS
Drugs and Reagents
Compound JNJ7777120 (JNJ; 1-[(5-chloro-1H-indol-2-yl)
carbonyl]-4-methylpiperazine), a potent and selective H4R 
antagonist, has been used at a concentration of 2.5  mg/kg of 
body weight (b.wt.). This compound was kindly provided by 
Abbreviations: αSMA, Alpha-smooth muscle actin; ECM, Extracellular matrix; 
8-OHdG, 8-Hydroxy-deoxy-guanosine; H4R, Histamine H4 receptor; IL-10, 
Interleukin-10; IL-1β, Interleukin-1β; i.p., Intra-peritoneal; IPF, Idiopathic 
pulmonary fibrosis; JNJ, JNJ7777120; MPO, Myeloperoxidase; OD, Optical density; 
PARP, Poly(ADP-ribose) polymerase; PAO, Pressure at the airway opening; PAS, 
Periodic acid-Schiff; PGE2, Prostaglandin E2; TGF-β, Transforming growth factor-β; 
TNF-α, Tumor necrosis factor-α; WT, Wild-type; VUF, VUF8430.
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Dr. Robin Thurmond (Janssen Research & Development, USA). 
Compound VUF8430, (VUF; 2-[(aminoiminomethyl)amino] ethyl 
carbamodithioic acid ester, S-(2-guanidylethyl)-isothiourea), an 
H4R agonist, (Sigma-Aldrich, San Louis, MO, USA), was used 
at a concentration of 2 mg/kg b.wt. Bleomycin (Merck-Millipore, 
Burlington, MA, USA) was used at a concentration of 0.05  IU 
for each mouse and dissolved in 50  μl of saline, in order to 
obtain the bleomycin-induced model of lung fibrosis. The drug 
doses and frequency of administrations were selected according 
to previous papers (Rosa et  al., 2014; Lucarini et  al., 2016).
Animals
Male wild-type (WT) C57BL/6 mice, approximately weighing 
25–30  g and 8–9  weeks old, purchased from a commercial 
dealer (Harlan, Udine, Italy), and male C57BL/6 PARP-1 deficient 
mice (PARP-1−/−) (Wang et  al., 1995), comparable in mice 
strain, age, and weight with WT mice, were used for the 
experiments. All the animals were fed with standard diet and 
water at libitum and housed under a 12 h light/dark photoperiod 
at 22°C for at least 48  h before the experiments.
The study protocol complied with the recommendations of 
the European Economic Community (86/609/CEE) and the 
Declaration of Helsinki on animal experimentation and was 
approved by the animal Ethical and Care Committee of the 
University of Florence (Florence, Italy) and by the Italian Health 
Ministry (Authorization n 874/2017-PR). Experiments were 
performed at the Centre for Laboratory Animal Housing and 
Experimentation (CeSAL) at the University of Florence. The 
ARRIVE guidelines were considered (McGrath et  al., 2010).
Surgery and Treatments
Seventy mice (30 WT and 40 PARP-1−/−) were anesthetized 
with zolazepam/tiletamine (Zoletil, 50/50  mg/ml, Virbac Srl, 
Milan, Italy; 50  μg/g, in 100  μl of saline, i.p.); 50 of them (20 
WT and 30 PARP-1−/−) were intra-tracheally treated with 
bleomycin (0.05 IU in 50 μl of saline), and the other 20 (10 WT 
and 10 PARP-1−/−) were intra-tracheally treated with 50  μl of 
saline (referred to as non-fibrotic negative controls, Naive).
Ten bleomycin-treated WT and 10 bleomycin-treated PARP-1 
deficient mice received two daily intra-peritoneal (i.p.) injections 
of 100  μl of JNJ solution (2.5  mg/kg; i.p.), after bleomycin 
administration and for the next 21  days. These are referred 
to as Bleomycin+JNJ treated groups. Ten bleomycin treated 
PARP-1−/− mice received two daily intra-peritoneal injection 
of 100  μl of VUF solution (2  mg/kg; i.p.), after bleomycin 
administration and for the next 21  days. These are referred 
to as Bleomycin+VUF treated group. Ten WT mice and 10 
PARP-1−/− mice were treated only with vehicle (PBS) and 
referred to as fibrotic positive controls (Bleomycin+Vehicle).
Functional Assay of Fibrosis
At the end of the treatment period, all mice were subjected 
to the measurement of airway resistance to inflation and static 
lung compliance, functional parameters for fibrosis-induced 
lung stiffness. The measurement is performed using a constant 
volume mechanical ventilation method with constant number 
of breaths in a minute; the static compliance determination 
is performed applying a positive end-expiratory pressure of 
3  cm H2O, to mimic spontaneous ventilation (Pini et  al., 2010, 
2012; Manni et al., 2016). Briefly, a 22-gauge cannula (Venflon 2; 
Viggo Spectramed, Windlesham, UK, 0.8  mm diameter) was 
inserted into the trachea of the anesthetized mouse. The animal 
was ventilated with a small-animal respirator (Ugo Basile, 
Comerio, Italy) adjusted to deliver a tidal volume of 0.8  ml 
at a rate of 20 strokes/min. A high-sensitivity pressure transducer 
(settings: gain 1, chart speed 25 mm/sec.; P75 type 379; Harvard 
Apparatus Inc., Holliston, MA, USA) connected to a polygraph 
(Harvard Apparatus Inc. Edenbridge, UK; settings: gain 1, chart 
speed 25  mm/s) was used to register the changes in lung 
resistance to inflation, defined as the pressure at airway opening 
(PAO). Changes in lung resistance to inflation, expressed as 
millimeters on the chart and registered for at least 3  min, 
were carried out not less than 40 consecutive tracings of 
respiratory strokes and then averaged. For static lung compliance 
determination, multiple linear regression was used to fit pressure 
and volume in each individual mouse to the linear model of 
the lung (Manni et  al., 2016).
Lung Tissue Sampling
After PAO measurements, the animals were killed with lethal 
dose of anesthetic drugs. The whole left lungs were removed 
and fixed with 4% paraformaldehyde in PBS for histological 
analysis. The right lungs were weighed, quickly frozen, and 
stored at −80°C. For biochemical measurements, the samples 
were thawed at 4°C, homogenized on ice in 50  mM Tris-HCl 
buffer (180  mM KCl and 10  mM EDTA, pH  7.4), and then 
centrifuged for 30  min at 10,000  g at 4°C, unless otherwise 
reported. The homogenized supernatants were collected.
Histology and Assessment of Collagen 
Deposition, Goblet Cell Hyperplasia, and 
Smooth Muscle Layer Thickness
Six μm thick histological sections were cut from the paraffin-
embedded lung samples. In order to minimize artefactual 
differences in the staining process, all sections were stained 
in a single session. A digital camera connected to a light 
microscope equipped with an ×20 objective was used to randomly 
take photomicrographs of the histological slides. Computer-
aided densitometry was performed to obtain quantitative 
assessment of the stained sections. The free-share ImageJ 1.33 
image analysis program1 was used to measure optical density 
(OD) and surface area. For each measured parameter, values 
are means ± SEM of the OD measurements (arbitrary units) 
of individual mouse (five images each) from every experimental 
groups (tested blind).
The assessment of lung collagen was obtained by staining 
the histological sections with a simplified Azan method for 
collagen fibers (Smolle et  al., 1996), omitting azocarminium 
and orange G to reduce parenchymal tissue background. OD 
measurements of the aniline blue-stained collagen fibers were 
1 http://rsb.info.nih.gov/ij
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performed after selection of a correct threshold to eliminate 
aerial air spaces and bronchial/alveolar epithelium (Formigli 
et  al., 2007). To confirm the assessment of lung collagen, the 
Picrosirius red staining was carried out; the sections were 
stained in 0.1% Direct Red 80/Sirius Red F3B (Sigma-Aldrich) 
in saturated picric acid at room temperature for 1  h, and 
then they were differentiated in 0.5% acetic acid, prior to 
dehydration, clearing, and mounting (Lattouf et  al., 2014; 
Marcos-Garcés et  al., 2017).
Moreover, lung tissue sections were stained with hematoxylin 
and eosin or with periodic acid-Schiff (PAS) staining for mucins 
in order to obtain morphometry of smooth muscle layer 
thickness and bronchial goblet cell number, respectively, both 
key markers of airway remodeling. Digital microphotographs 
of small-sized bronchi were taken randomly. The thickness of 
the bronchial smooth muscle layer was measured on the digitized 
images using the above-mentioned software. Total bronchial 
epithelial cells and PAS-stained goblet cells were counted on 
bronchial cross-section profiles, and the percentage of goblet 
cells was calculated.
Western Blot Analysis of PARylated 
Protein Content
For determination of PARylated protein content in the lung, 
tissues were homogenized in RIPA buffer plus a cocktail of 
protease inhibitors and centrifuged at 12,000  g for 5  min. 
Supernatants were collected, and total protein levels were 
measured using Micro BCA Protein Assay (ThermoFisher 
Scientific, Waltham, MA, USA). Thirty μg of proteins were 
used for Western blot analysis, with a mouse monoclonal anti-
PAR(10H) antibody (Alexis Biochemicals, Florence, Italy) diluted 
1:1,000 in PBS-T containing 5% non-fat dry milk. The PAR(10H) 
monoclonal antibody recognizes poly(ADP-ribose) synthesized 
by PARP enzymes. A suitable peroxidase-conjugated secondary 
antibody (diluted 1:5,000  in PBS-T containing 5% non-fat dry 
milk) was used to determine the binding of the primary 
antibody. The loading transfer of equal amounts of proteins 
was controlled by reblotting the membrane with an anti-β-
actin antibody (diluted 1:20,000 in 5% non-fat dry milk-PBS-T, 
Sigma-Aldrich). Bands were visualized by enhanced 
chemiluminescence (Luminata Crescendo Western HRP substrate, 
Merck Millipore) and quantified by densitometric analysis with 
the ImageJ software.
Determination of Transforming Growth 
Factor-β (TGF-β), Interleukin-1β (IL-1β), 
Tumor Necrosis Factor-α (TNF-α), and 
Interleukin-10 (IL-10)
The levels of TGF-β, the main profibrotic cytokine involved 
in fibroblast activation, and two pro-inflammatory cytokines, 
IL-1β and TNF-α, were measured on aliquots (20  μl) of 
lung samples homogenated in PBS by using the FlowCytomix 
assay (Bender Medsystems GmbH, Vienna, Austria), following 
the protocol provided by the manufacturer. Briefly, 
suspensions of anti-TGF-β, IL-1β or TNF-α-coated beads 
were incubated with the supernatant samples and then with 
biotin-conjugated secondary antibodies and streptavidin-
phycoerythrin. Fluorescence was read with a cytofluorimeter 
(CyFlow® Space, Partec, Carate Brianza, MB, Italy).
The levels of the anti-inflammatory cytokine IL-10 were 
measured on aliquots (100 μl) of lung homogenate supernatants 
by using the mouse IL-10 ELISA Ready-SET&Go!® assay 
(eBioscience, San Diego, USA), following the protocol provided 
by the manufacturer. Values are indicated as means ± SEM 
of 10 individual mice from each group and expressed as pg/μg 
of total proteins determined over an albumin standard curve.
Determination of αSMA Deposition
Immunofluorescence analysis was performed as previously 
described (Lucarini et  al., 2014). Briefly, histological sections 
of 5  μm thick were deparaffinized and boiled for 10  min in 
sodium citrate buffer (10  mM, pH  6.0, Bio-Optica, Milan, 
Italy) for antigen retrieval. A pre-incubation in 1.5% bovine 
serum albumin (BSA) in PBS, pH  7.4 for 20  min at RT was 
necessary to minimize the unspecific binding; whereupon, the 
sections were incubated overnight at 4°C with rabbit monoclonal 
anti-αSMA antibody (1:200 ABCAM, USA) followed by goat 
anti-rabbit Alexa Fluor 488-conjugated IgG (1:300 Invitrogen, 
San Diego, CA, USA) for 2  h in the dark at RT. Negative 
controls were performed with non-immune rabbit serum 
substituted for the primary antibody. The counterstaining of 
nuclei was obtained with 4′,6-diamidino-2-phenylindole (DAPI). 
Representative images were acquired with an Olympus BX63 
microscope coupled to CellSens Dimension Imaging Software 
version 1.6 (Olympus, Milan, Italy). αSMA expression was 
quantified by densitometric analysis of fluorescence signal 
intensity, measured on digitized images using ImageJ software2. 
Twenty regions of interest (ROI) were evaluated for each sample. 
Values are expressed as mean ± SEM of the OD measurements 
(arbitrary units) of individual mouse from the different 
experimental groups.
Determination of  
8-Hydroxy-Deoxyguanosine (8-OHdG)
Lung DNA isolation was performed as previously described 
(Lodovici et  al., 2000) with minor modifications. In brief, lung 
samples were homogenized in 1  ml of 10  mM PBS, pH  7.4, 
sonicated on ice for 1  min, added to 1  ml of 10  mM Tris-HCl 
buffer, pH  8, containing 10  mM EDTA, 10  mM NaCl, and 
0.5% SDS, and incubated for 1  h at 37°C with 20  μg/ml 
RNase 1 (Sigma-Aldrich). Samples were incubated at 37°C 
overnight in the presence of 100  μg/ml proteinase K (Sigma-
Aldrich). The mixture was extracted with chloroform/isoamyl 
alcohol (10:2, v/v). DNA was precipitated from the aqueous 
phase with 0.2 volumes of 10 M ammonium acetate, solubilized 
in 200  μl of 20  mM acetate buffer, pH  5.3, and denatured at 
90°C for 3  min. The extract was supplemented with 10  IU 
of P1 nuclease (Sigma-Aldrich) in 10  μl and incubated for 
1 h at 37°C with 5 IU of alkaline phosphatase (Sigma-Aldrich) 
in 0.4  M phosphate buffer, pH  8.8. All the procedures were 
2 http://rsbweb.nih.gov/ij
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performed in the dark. The mixture was filtered by an Amicon 
Micropure-EZ filter (Merck-Millipore), and 100  μl of each 
sample were used for 8-OHdG determination by using an 
ELISA kit (JalCA, Shizuoka, Japan), following the instructions 
provided by the manufacturer. The absorbance of the chromogenic 
product was measured at 450  nm. The results were calculated 
from a standard curve based on an 8-OHdG solution and 
expressed as ng of 8-OHdG/ng of total DNA.
Determination of Myeloperoxidase  
Activity (MPO)
Frozen lung samples were weighed and homogenized (10 μl/mg 
of tissue) in 0.2  M phosphate buffer solution (PBS), pH  6, 
supplemented with protease inhibitors (1  mM PMSF, 20  μg/ml 
leupeptin, 1 μg/ml pepstatin, 1 mg/ml Pefabloc SC, and 2.5 μg/
ml aprotinin, Sigma-Aldrich) and were centrifuged at 10,000  g 
at 4°C for 30  min. MPO was measured in the supernatants 
with a specific immunoassay kit (CardioMPO; PrognostiX, 
Cleveland, OH), according to the manufacturer’s instructions 
(Pini et  al., 2010). Total protein concentration in the lung 
tissue samples was determined over an albumin standard curve. 
The results are expressed as picomoles/mg of protein. Values 
are means  ±  SEM of individual mice from different 
experimental groups.
Statistical Analysis
Data were reported as mean values (±SEM) of individual 
average measures of the different animals per group, for each 
assay. Significance of differences among the groups was evaluated 
by one-way ANOVA followed by Newman-Keuls post hoc 
test for multiple comparisons. Calculations were made with 
Prism 5 statistical software (GraphPad Software, Inc., USA). 
A probability value p < 0.05 was considered significant.
RESULTS
Functional Assay of Fibrosis (PAO)
Intra-tracheal administration of bleomycin causes an increase 
in airway stiffness leading to a clear-cut elevation of the pressure 
in airway opening (PAO) (Masini et  al., 2005). Intra-tracheal 
delivery of bleomycin to rodents results in an intense 
inflammatory reaction within the first week, followed by the 
development of fibrosis by day 14, with maximal responses 
at day 21. Therefore, bleomycin administration caused a significant 
increase in airway stiffness, as judged by the elevation of PAO 
in the fibrotic positive controls (Bleomycin+Vehicle) compared 
with the non-fibrotic negative ones (Naïve), both in WT and 
PARP-1−/− mice (Figure 1).
After 21  days, the treatment with JNJ significantly reduces 
PAO both in WT and in PARP-1−/− mice, in comparison to the 
relative group of animals treated with Vehicle; while VUF treatment 
seems to be not significantly effective in reducing the bleomycin-
induced airway stiffness (Figure 1). The selected doses were 
based on previous papers (Pini et al., 2012; Lucarini et al., 2016). 
These results confirm our previous observation that H4R ligands 
could have beneficial effects in decreasing lung fibrosis in WT 
(Lucarini et  al., 2016) and in PARP-1−/− animals, indicating that 
the treatment with H4R antagonists exerts its beneficial effects 
also in situation of PARP-1 deletion.
Changes in PARP-1 Activity
It has been demonstrated that bleomycin administration increases 
PARP activity in mouse lung tissues (Genovese et  al., 2005). 
Moreover, previous studies provided evidence that PARylated 
protein levels, the major products of PARP activity, are 
significantly increased in lung homogenates of WT mice treated 
with bleomycin, while the treatment with HYDAMTIQ, a potent 
PARP-1/2 inhibitor, dose-dependently, prevents this PARylation 
(Lucarini et  al., 2017).
To evaluate the effects of intra-tracheal administration of 
bleomycin on PARP activity, we  investigated the formation of 
polyADP ribose (PAR) polymers in mouse lung tissues in WT 
and PARP-1−/− mice. As shown in Figure 2 and in Supplementary 
Figure 1, Western blot analysis with anti-PAR antibodies report 
an increase in PARylated protein content in lung homogenates 
of WT and in PARP-1−/− mice treated with bleomycin (Vehicle), 
compared to non-fibrotic controls (Naїve). Treatment with the 
H4R antagonist reduces the PARylated protein content in WT 
animals. Interestingly, our results indicate a reduction of PARylated 
protein levels in the lung tissues of PARP-1−/− mice treated 
with JNJ, compared to those treated with VUF, suggesting a 
positive role of H4R antagonism in suppressing catalytic activity 
of PARP enzymes different from PARP-1.
Histological and Morphometric Analysis
Acute inflammatory events and deposition of collagen fibers 
cause a pathological remodeling of the parenchyma of the lungs. 
Morphological observation and computer-aided densitometry 
FIGURE 1 | Spirometric evaluation. Bar graph and statistical analysis of 
differences in PAO values (means ± SEM) between different experimental 
groups (n = 10 animals per group). **p < 0.01 and ***p < 0.001 vs. 
Bleo+Vehicle of each related group WT or PARP−/− (Bleo = Bleomycin).
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on Azan-stained sections (Figure 3A) reveal a significant increase 
in collagen deposition in the lungs of all bleomycin-treated 
animals (Vehicle) compared to the non-fibrotic negative controls 
(Naïve). As already published, in WT animals, H4R antagonists 
reduce the deposition of collagen fibers in lungs compared to 
Vehicle (Rosa et  al., 2014; Lucarini et  al., 2016). The treatment 
with JNJ causes an important and significant reduction of the 
amount of lung collagen fibers in PARP-1−/− mice compared 
to Vehicle group. A slight effect is reported in VUF treated 
mice. To confirm the assessment of lung collagen, the Picrosirius 
red was used as second staining method; this specific staining 
for collagen (Lattouf et  al., 2014; Marcos-Garcés et  al., 2017) 
confirms the results obtained with Azan staining (Figure 3B).
We also evaluated the bronchial remodeling by measuring 
the number of goblet cells and the thickness of the smooth 
muscle layer, key histological parameters of inflammation-
induced adverse airway remodeling (Bai and Knight, 2005). 
These two parameters are increased after intra-tracheal injection 
of bleomycin, both in WT and PARP-1 deficient mice. The 
treatment with JNJ significantly reduces the percentage of 
PAS-positive goblet cells over bronchial epithelial cells 
(Figure  4A), as well as the thickness of the airway smooth 
muscle layer (Figure 4B). On the contrary, VUF administration 
has no effect on both histological parameters, confirming our 
previous published results that on the effect of H4R antagonists 
on goblet cells and thickness of the smooth muscle layer in 
lungs, (Rosa et  al., 2014; Lucarini et  al., 2016).
TGF-β Signaling Pathway
An increased TGF-β expression and an amplified TGF-β 
signaling through Smad pathways contribute to the establishment 
and development of pulmonary fibrosis (Leask and Abraham, 
2004; Chen et al., 2013; Chitra et al., 2015). Our results clearly 
indicate that TGF-β, a major pro-fibrotic cytokine, is increased 
in the vehicle groups, both in WT and PARP-1−/− mice. Systemic 
administration of JNJ causes a significant decrease of the 
levels of TGF-β in WT as well as PARP-1−/− animals, while 
the treatment with the H4R agonist has no effect on the 
production of this cytokine (Figure 5A). These results 
demonstrate the anti-fibrotic activity of JNJ both in WT and 
in PARP-1−/− mice.
Fibroblast Activation
Transforming growth factor-β signaling has been reported to 
regulate the expression of αSMA, a marker of fibroblast activation, 
and myofibroblasts differentiation (Martin et  al., 2007; Conte 
et  al., 2014). To investigate the expression of αSMA during 
the fibrotic process, we performed immunofluorescence analysis 
in mouse lung tissues. Our results show a significant increase 
of αSMA levels in bleomycin-exposed PARP-1−/− animals 
(Figures 5B,C). Treatment with JNJ significantly reduces αSMA 
levels in lung tissue of PARP-1−/− mice compared to the vehicle 
group. Systemic administration of the H4R agonist provides 
no changes in αSMA lung levels. These results indicate that 
the use of an H4R antagonist, in the absence of PARP-1 enzyme, 
reduces the activation of fibroblasts and myofibroblasts 
differentiation and consequently the development of progressive 
fibrotic disease in bleomycin-exposed animals.
Effects of H4R Ligands on  
Pro-Inflammatory Cytokine Production
Chronic inflammation is determined by pathological wound-
healing response, resulting in the accumulation of permanent 
scar tissue at the site of injury and consequently in the 
development of progressive fibrotic disease (Wynn and 
Ramalingam, 2012). Based on this evidence, we  evaluated the 
late (21 days after challenge) inflammatory response to bleomycin 
by measuring the pro-inflammatory cytokines IL-1β and TNF-α, 
in lung homogenates of WT and PARP-1−/− mice. Bleomycin 
treatment increases the levels of IL-1β and TNF-α both in WT 
and PARP-1−/− mice; of note, in PARP-1−/− mice, this increase 
is less pronounced in comparison to WT mice. The systemic 
administration of JNJ significantly reduces the increase in both 
groups of animals, but in PARP-1−/− mice, this reduction is 
more evident. The treatment with VUF is not effective in the 
reduction of inflammatory cytokine production (Figures 6A,B).
A
B
FIGURE 2 | PARP activity. (A) Western blot analysis of PARylated protein 
content in lung samples from each experimental group. (B) Densitometric 
analysis was normalized on β-actin (n = 10 animals per group). *p < 0.05 and 
**p < 0.01 vs. Bleo+Vehicle of each related group WT or PARP−/− 
(Bleo = Bleomycin).
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FIGURE 3 | Evaluation of lung fibrosis. (A) Representative micrographs of Azan-stained sections from mice of the different experimental groups. Collagen fibers are 
stained deep blue. The lung from fibrotic controls treated with vehicle show marked fibrosis in peribronchial stroma, which is absent in non-fibrotic negative control 
lungs (Naïve) and reduced in JNJ treated animals. Bar graph showing the optical density (OD) (means ± SEM) of Azan-stained collagen fibers of the different 
experimental groups (n = 10 animals per group). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. Bleomycin+Vehicle of each related group. (B) Representative 
micrographs of Picrosirius red-stained sections from mice of the different experimental groups. Collagen fibers are stained in red. Bar graph showing the optical 
density (OD) (means ± SEM) of Picrosirius red-stained collagen fibers of the different experimental groups (n = 10 animals per group). *p < 0.05, **p < 0.01, and 
***p < 0.001 vs. Bleomycin+Vehicle of each related group.
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FIGURE 4 | (A) Goblet cell hyperplasia. Representative micrographs of PAS-stained sections. Bar graph showing fraction of goblet cells (% means ± SEM) in the 
different experimental groups (n = 10 animals per group). *p < 0.05 and ***p < 0.001 of vs. Bleo+Vehicle of each related group. (B) Evaluation of muscular 
remodeling. Smooth muscle thickness was assessed by computer aided morphometry on H&E-stained lung sections. Representative micrographs of the sections. 
Bar graph showing the thickness of the muscular fiber (means ± SEM) in the different experimental groups (n = 10 animals per group). **p < 0.01 and ***p < 0.001 
vs. Bleo+Vehicle of each related group.
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FIGURE 5 | (A) Evaluation of TGF-β1 production. Bar graph showing lung 
tissue levels of the profibrotic cytokine TGFβ1 (means ± SEM) of the 
different experimental groups (n = 10 animals per group). *p < 0.05, 
**p < 0.01, and ***p < 0.001 vs. Bleo+Vehicle of each related group.  
(B) Evaluation of fibroblast activation. Immunofluorescence staining of lung 
tissue sections labeled with alpha smooth muscle actin (αSMA) (green) and 
nuclei (blue) counterstained with DAPI (20×). Images in the panels show 
the inhibition of αSMA expression, a marker of the transformation of 
fibroblasts into myofibroblasts (n = 10 animals/group). (C) Bar graph 
shows the optical density (means ± SEM) in the different experimental 
groups (n = 10 animals per group). *p < 0.05 and **p < 0.01 vs. 
Bleo+Vehicle. (Bleo = Bleomycin).
A
B
C
FIGURE 6 | Determination of IL-1β (A), TNF-α (B), and IL-10 (C) levels in the 
supernatant of lung tissue homogenates. The values are expressed as pg/μg 
of total proteins (n = 10 animals per group). Values are mean ± SEM. 
*p < 0.05, **p < 0.01, and ***p < 0.001 vs. Bleo+Vehicle of each related 
group (Bleo = Bleomycin).
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In order to confirm the anti-inflammatory activity of the 
H4R antagonist, we evaluated the levels of interleukin-10 (IL-10), 
the most potent anti-inflammatory cytokine involved in resolution 
of different acute and chronic inflammatory diseases (Ajuebor 
et  al., 1999). Our results report a significant increase in the 
production of IL-10  in WT and PARP-1−/− mice treated with 
JNJ in comparison to PARP-1−/− mice treated with vehicle or 
VUF (Figure 6C).
Our findings support the hypothesis that H4R antagonism 
exerts anti-inflammatory and anti-fibrotic effects in a model 
of bleomycin-induced lung fibrosis.
Determination of Leukocyte Lung 
Infiltration and of Oxidative Stress Marker
Lung MPO is a peroxidase enzyme abundantly expressed in 
neutrophils and monocytes/macrophages granules, and it is 
considered a reliable marker for leukocyte accumulation in 
inflamed tissues (Mullane et  al., 1985). Levels of MPO were 
very low in the Naïve groups of both WT and PARP−/− mice; 
MPO levels increased significantly in the bleomycin-treated 
mice (Vehicle groups of WT and PARP−/− mice). A significant 
decrease in MPO was demonstrated after treatment with 
JNJ in WT and PARP−/− groups of animals in comparison 
to Vehicle; treatment with VUF has some non-significant 
effects (Figure 7A).
The determination of 8-OHdG, a biological marker of DNA 
damage under oxidative stress, demonstrates that it is 
significantly increased in bleomycin-exposed animals (Vehicle), 
compared with non-fibrotic negative ones (Naïve). Interestingly, 
our results show a significant reduction of 8-OHdG levels in 
WT and PARP-1−/− animals treated with JNJ (Figure 7B), 
but not with VUF.
DISCUSSION
Pulmonary fibrosis is an unmet medical need with a median 
survival of ~3  years since diagnosis. It is often severe and 
difficult to manage, resulting in a chronic condition that 
negatively affects the quality of life. The pharmacological therapy 
of pulmonary fibrosis is challenging, and for many patients, 
effective treatment is lacking. Therefore, novel therapeutic 
strategies are required (Wynn, 2007; Paz and Shoenfeld, 2010).
Recent studies demonstrated the involvement of PARP 
enzymes in modulating airway inflammation and fibrosis. 
Particularly, PARP-1 inhibition improves functional, 
biochemical, and morphometric parameters in an in vivo 
allergen-induced asthma-like reaction model (Lucarini et  al., 
2014) and in a bleomycin-induced pulmonary fibrosis model 
(Lucarini et  al., 2017).
Histamine H4 receptor (H4R), the last discovered histamine 
receptor subtype, is functionally expressed and distributed in 
white blood cells, mast cells, eosinophils, dendritic cells, and 
T cells (Gutzmer et al., 2009). Recent evidence strongly suggests 
that H4R ligands might be  exploited as potential therapeutics 
in modulating allergy, inflammation, autoimmune disorders, 
and possibly cancer. In an animal model of allergic airway 
inflammation, H4R-knockout mice present lower inflammation, 
reduced pulmonary infiltrate of lymphocytes and eosinophils, 
and an attenuated Th2 response (Dunford et al., 2006). Moreover, 
blocking H4R in a model of pulmonary fibrosis alleviates the 
inflammatory response, reducing COX-2 expression and activity, 
leukocyte infiltration, TGF-β production, and collagen deposition 
(Lucarini et  al., 2016).
Although these findings suggest a promising therapeutic 
use for H4R antagonists in the modulation of chronic lung 
A
B
FIGURE 7 | (A) MPO levels, a marker for leukocyte infiltration, are shown in 
the histogram. Values are expressed as mean ± SEM, expressed as 
picomoles per milligram of lung tissue protein (n = 10 animals per group) 
***p < 0.001 vs. Bleo+Vehicle of each related group (Bleo = Bleomycin); 
#p < 0.05 vs. Bleo+VUF. (B) Evaluation of oxidative stress parameter in lung 
tissue. Bar graph shows the levels of 8-OHdG, a marker of free radicals-
induced by DNA damage, (mean ± SEM) in the different experimental groups 
(n = 10 animals per group). *p < 0.05, **p < 0.01 vs. Bleo+Vehicle of each 
related group (Bleo = Bleomycin).
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diseases, the biochemical basis underlying the protective and 
beneficial effects of these drugs are unknown and need to 
be  further elucidated.
Here, we  tested the possible role that PARP-1 may have in 
the mechanism of action of H4R antagonists. Briefly, 
we demonstrate that JNJ, a selective antagonist of the histamine 
H4R, exerts its anti-inflammatory and anti-fibrotic properties 
independently of PARP-1 signaling pathway, in an in vivo 
mouse model of bleomycin-induced lung fibrosis.
Chronic inflammation is determined by pathological wound-
healing response, resulting in the accumulation of scar tissue 
and consequently in the development of progressive fibrotic 
disease (Wynn and Ramalingam, 2012). Our model of pulmonary 
fibrosis is well described and widely accepted and includes an 
acute inflammatory phase (7–9  days), followed by a chronic 
inflammatory infiltrate and fibrotic process in the next 2  weeks, 
with maximal responses at day 21 (Moore and Hogaboam, 2008).
Therefore, we  evaluated the inflammatory response to 
bleomycin in lung homogenates of WT and PARP-1−/− mice. 
The results show that the treatment with JNJ significantly 
reduces the production of IL-1β and TNF-α pro-inflammatory 
cytokines and the activity of MPO, as well as the levels of 
8-OHdG, a reliable marker of oxidative stress, in WT and in 
PARP-1−/− mice. Collectively, our results demonstrate that H4R 
antagonist’s anti-inflammatory and anti-fibrotic effects are not 
dependent on PARP-1 expression, thus adding further evidence 
on the role of H4R in controlling leukocyte trafficking and 
pro-inflammatory responses (Zampeli and Tiligada, 2009).
Previous data demonstrated a role for histamine and H4R 
in the production of TGF-β, the major pro-fibrotic cytokine, 
and in fibroblast activation (Cowden et al., 2010). The cytokine 
TGF-β has been proposed to play a key role in lung fibrosis 
(Tatler and Jenkins, 2012), and drugs able to control TGF-β 
expression and/or signaling seem to be  active in reducing 
fibroblast activation and clinical progression of the disease 
(Bonniaud et  al., 2005). The TGF-β overexpression has been 
repeatedly associated to lung fibrosis (Sime et  al., 1997), and 
the administration of TGF-β neutralizing antibodies was able 
to prevent the disease.
Here, we  report the positive effects of the H4R antagonist 
on the lung TGF-β pathway, showing that the treatment with 
JNJ significantly reduces TGF-β levels also in PARP-1−/− mice. 
Thus, our results indicate that H4R antagonists can ameliorate 
lung fibrosis independently of PARP-1 expression. To further 
confirm the effects of the H4R antagonist JNJ, we  performed 
experiments also with VUF8430, introduced as a selective H4R 
agonist. Surprisingly, in our model, VUF has some unexpected 
effects in reducing features of lung injury, in functional assay 
as well as α-SMA and collagen deposition. This discrepancy 
could be  explained because this H4R agonist with minor 
modification on imidazole moiety has affinity also for H3R 
(Lim et  al., 2009), thus reducing the endogenous release of 
histamine and H4R activation.
PARP-1 activity contributes to lung fibroblast activation 
and induces their proliferation with increased expression 
of αSMA, which plays a pivotal role in lung fibrosis 
(Hu et  al., 2013). In order to confirm the above results, 
we  demonstrate a significant reduction of αSMA levels in 
PARP-1−/− mice treated with JNJ, suggesting that the use 
of an H4R antagonist, in the absence of PARP-1 enzyme, 
strongly reduces the activation of fibroblasts and the 
differentiation of myofibroblasts, consequently blocking the 
development of progressive fibrotic disease.
Overall, these findings suggest that PARylation is a key 
factor for the pathogenesis of pulmonary fibrosis and provide 
evidence that PARP-1 and H4R are independently involved in 
the signaling pathways activated during inflammatory and 
fibrotic processes. The association of PARP-1 deficiency and 
H4R antagonist treatment exerts a cross-talk response with 
anti-inflammatory and anti-fibrotic effects, decreasing 
bronchoconstriction and airway inflammation, as also shown 
by the reduction of the percentage number of goblet cells and 
the thickness of the smooth muscle layer, key parameters of 
inflammation-induced adverse airway remodeling.
Actually, the treatment of idiopathic pulmonary fibrosis 
is based on the use of either pirfenidone, a drug able to 
reduce the production of fibrogenic mediators, such as TGF-β, 
and inflammatory mediators, such as TNFα and IL-1β 
(Inomata et  al., 2015), or nintedanib, a tyrosine kinase 
inhibitor able to reduce the transduction pathway of growth 
factor receptors, such as platelet-derived growth factor receptor, 
fibroblast growth factor receptor, and vascular endothelial 
growth factor receptor, and to reduce the transduction 
pathways leading to cell activation and proliferation 
(Nanthakumar et  al., 2015). Both agents have recently been 
introduced into clinical practice showing their ability to 
ameliorate lung fibrotic processes; however, it is still not 
clear whether these agents have a clinically meaningful 
efficacy in long-term patient survival (Karimi-Shah and 
Chowdhury, 2015). Effective therapies to contrast airway 
inflammation and remodeling are not available, and novel 
therapeutic strategies are needed as alternative options when 
the standards of care are not enough.
In this study, we  showed that the beneficial effects of H4R 
antagonists in reducing progressive pulmonary fibrosis are not 
dependent upon PARP-1.
In conclusion, the therapeutic potential of the combination 
of H4R antagonists with non-toxic doses of selective PARP-1 
inhibitors could significantly reduce the development of 
pulmonary fibrosis. Although JNJ itself is emerging as a promising 
therapeutic agent in lung inflammation, the combination with 
PARP inhibitors could have an advantage over the single drug 
for the potentiating effect on the inhibition of inflammatory 
and pro-fibrotic parameters.
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